Sign up
Pharma Capital

The 'end of the marathon' for Motif Bio's Iclaprim

Vadim Alexandre, head of research at Northland Capital Partners, discusses with Proactive Motif Bio Plc's (LON:MTFB, NASDAQ: MTFB) lead drug, a next generation antibiotic, successfully negotiating a crucial final-stage clinical study.

The REVIVE-2 Phase III trial pitted Motif’s iclaprim treatment against vancomycin in patients with acute bacterial skin and skin structure infections (ABSSSI).

 

View full MTFB profile

Motif Bio Plc Timeline

Article

Motif Bio : The home plate beckons

View All

© biotech Capital 2017

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.